10 November 2022

New Invivoscribe FLT3 ITD MRD Assay for RUO

We are excited to announce that Invivoscribe has expanded its FLT3 portfolio to include an in-house end-to-end Research Use Only kit for Acute Myeloid Leukemia (AML) measurable residual disease (MRD) research.

The FLT3 ITD MRD MRD Assay is a targeted, deep-sequencing assay identify internal tandem duplications (ITD), the most common mutation of the FLT3 gene1. Unlike flow cytometry assays which require fresh sample and are highly subjective, this assay is designed for use with previously isolated DNA for scalable sample batching and an automated Linux-based software, circumventing the need for costly in-house bioinformatics expertise.

This comprehensive assay enables multiplexing of up to 21 subjects. Generating an objective result at a sensitivity level of 5×10-5, the FLT3 ITD MRD assay enables the use of MRD as a reliable biomarker in longitudinal studies of AML.

Key benefits

  • In-house MRD testing for faster, cost-effective results
  • Streamlined workflow reduces errors and TAT
  • Scalable for low and high-throughput labs
  • Software can integrate with LIMs to automate a pipeline
  • Diagnostic sample is not required

Ordering information

FLT3 ITD MRD Assay (MiSeq) (14120019)
FLT3 ITD MRD v1.2 Software (MiSeq) (14120029)
The NGS-based FLT3 ITD MRD Assay and FLT3 ITD MRD v1.2 Software are for Research Use Only. Not intended for diagnostic purposes.

Bio-Connect Diagnostics supplies Invivoscribe products in the Benelux. If you have any questions, please contact the helpdesk.

New Invivoscribe FLT3 ITD MRD Assay for RUO

Related articles

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

we Connect you
Need help? Contact our technical support